Form S-1/A ZyVersa Therapeutics,
Tweet
Share
E-mailhttp://archive.fast-edgar.com/20230630/AL22W22CZM2RB2S322292CY2OPPQRZ22Z252
Filed on: June 30, 2023
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Takeda's zasocitinib beats deucravacitinib in psoriasis study
- Atossa Therapeutics raises $4.5 million in registered direct offering
- Enliven Therapeutics prices upsized public offering at $37.50 per share
Create E-mail Alert Related Categories
SEC FilingsRelated Entities
S3, S1Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
